

► FTSE Investor Update

Wednesday 31st August 2022

Centrica to give 10% of British Gas energy profits to poorer customers

The Sun broke a story last week in which **Centrica (CNA)** CEO, Chris O'Shea told the newspaper that the energy provider would increase support for customers ahead of a rise in a price cap on default tariffs.

Centrica will donate £12m of its £98m first-half pre-tax profit to an energy support fund.


Grants of up to £750 would be given to poorer customers and Centrica's pledge to donate 10% of profits every six months will last for the duration of the energy crisis.

Energy providers are being proactive in order to fend off calls for a windfall tax when a new Prime Minister is announced this autumn.

The shares have retraced lower in recent sessions, and a move back to support at 73p looks likely in the short-term.



CNA Daily Candle Chart




Vodafone to sell Hungarian business for \$1.8bn

Vodafone (VOD) announced last week that it will sell its Hungarian business for 715 billion forints (\$1.8bn) in cash.

The British mobile phone and broadband giant said it had agreed non-binding terms with the buyers, Hungarian 4iG – creating Hungary's second largest telecoms operator.

The deal is expected to be completed at the end of the year and does not include Vodafone's shared services business VOIS.

Part of Vodafone's strategy in recent years has been the selling of non-core assets to boost cashflow and fund the 5G rollout. The sale of its Hungarian business is just another in a long list of Vodafone's recent divestments.



VOD Daily Candle Chart



AstraZeneca's Farxiga cuts death risk in heart failure patients -study

AstraZeneca (AZN) run of strong trial results continued this month with its diabetes drug, Farxiga showing to significantly reduce the risk of hospitalisation and death in people with all types of heart failure.

The drug belongs to a class of medicines called SGLT2 inhibitors that were initially approved to treat type 2 diabetes. Since then, the drugs have been shown to benefit patients with chronic kidney and heart disease and prevent heart attacks.

AstraZeneca said Farxiga is the first heart failure medication to show mortality benefit across all forms of heart failure.



Detailed data from a study called 'DELIVER' showed Farxiga met the study's primary goal, inducing a statistically significant reduction in the risk of hear-related death, heart failure hospitalisation and urgent heart failure visits by 18%.

The study's finidng's have the potential to increase Farxiga's addressable patient population by 50% according to Ruud Dobber, who leads AstraZeneca's biopharma business.

AZN Daily Candle Chart



► Performance

FTSE Investor Update - Wednesday 31st August 2022

The table below shows performance data for every FTSE Investor open position since the service was launched in April 2022*

Name	Ticker	Growth	Value	Income	Open Date	Entry Price	Current Price*	Total Return**
Qinetiq	QQ.		✓		06/04/2022	316	352.6	13.08%
Unilever	ULVR		✓	✓	20/04/2022	3,431.20	3946	16.00%
Centrica	CNA		✓		04/05/2022	79.34	77.8	-1.94%
Vodafone	VOD			✓	18/05/2022	114.12	115.86	4.52%
Moneysupermarket.com	MONY		✓	✓	01/06/2022	183.11	193.6	5.72%
AstraZeneca	AZN	✓	✓		15/06/2022	9,821	11082	12.83%
ME Group	MEGP	✓			29/06/2022	76.40	90	17.80%
Ashtead	AHT	✓			13/07/2022	3,743	4281	14.37%
Auto Trader	AUTO	✓			27/07/2022	594.3	652.6	9.80%
JD Sports	JD.	✓	✓		10/08/2022	127.6	112.2	-12.06%
HSBC	HSBA		✓	✓	24/08/2022	522.90	528.5	1.07%

DISCLAIMER - All content is provided for general information only and should not be construed as any form of advice or personal recommendation. The provision of this content is not regulated by the Financial Conduct Authority.



*Prices correct as of 30th August 2022. **Total Return includes price movement and any dividends accrued during holding period. The table above shows ALL stock recommendations since FTSE Investor's launch on 6th April 2022. Please be aware that all entry and current price levels are mid-prices. No allowance for dealing costs, fees or taxes has been made. Past performance is not a guarantee of future performance.

All content is provided for general information only and should not be construed as any form of advice or personal recommendation. It does not take into consideration your personal circumstances, including your investment objectives, risk profile, tax status, knowledge and understanding or financial situation. Please ensure you fully understand the risks involved and seek independent advice if necessary.

Regency Research provides research for UK listed shares which can carry risk to your capital. The value of shares can fall as well as rise, which could mean getting back less than you originally invested. No liability is accepted for any loss or detriment in any way related to the content provided by Regency Research, the provision of which is not regulated by the Financial Conduct Authority.

Regency Research is a trading name of Regency Capital Group Ltd, registered in England and Wales (company number 11921999). Registered address at 35 Berkeley Square, Mayfair, London, United Kingdom, W1J 5BF. Regency Capital Group Ltd is authorised and regulated by the Financial Conduct Authority (FRN 916337). All prices quoted include VAT, charged at 20% (VAT number 397557923).

